首页> 外文期刊>Biology Open >Metabolite profile of a mouse model of Charcot–Marie–Tooth type 2D neuropathy: implications for disease mechanisms and interventions
【24h】

Metabolite profile of a mouse model of Charcot–Marie–Tooth type 2D neuropathy: implications for disease mechanisms and interventions

机译:Charcot–Marie–Tooth型2D神经病小鼠模型的代谢物特征:对疾病机制和干预措施的影响

获取原文
       

摘要

Charcot–Marie–Tooth disease encompasses a genetically heterogeneous class of heritable polyneuropathies that result in axonal degeneration in the peripheral nervous system. Charcot–Marie–Tooth type 2D neuropathy (CMT2D) is caused by dominant mutations in glycyl tRNA synthetase (GARS). Mutations in the mouse?Gars?gene result in a genetically and phenotypically valid animal model of CMT2D. How mutations in?GARS?lead to peripheral neuropathy remains controversial. To identify putative disease mechanisms, we compared metabolites isolated from the spinal cord of?Gars?mutant mice and their littermate controls. A profile of altered metabolites that distinguish the affected and unaffected tissue was determined. Ascorbic acid was decreased fourfold in the spinal cord of CMT2D mice, but was not altered in serum. Carnitine and its derivatives were also significantly reduced in spinal cord tissue of mutant mice, whereas glycine was elevated. Dietary supplementation with acetyl-L-carnitine improved gross motor performance of CMT2D mice, but neither acetyl-L-carnitine nor glycine supplementation altered the parameters directly assessing neuropathy. Other metabolite changes suggestive of liver and kidney dysfunction in the CMT2D mice were validated using clinical blood chemistry. These effects were not secondary to the neuromuscular phenotype, as determined by comparison with another, genetically unrelated mouse strain with similar neuromuscular dysfunction. However, these changes do not seem to be causative or consistent metabolites of CMT2D, because they were not observed in a second mouse?Gars?allele or in serum samples from CMT2D patients. Therefore, the metabolite ‘fingerprint’ we have identified for CMT2D improves our understanding of cellular biochemical changes associated with?GARS?mutations, but identification of efficacious treatment strategies and elucidation of the disease mechanism will require additional studies.
机译:Charcot–Marie–Tooth疾病包​​括遗传上异质的遗传性多发性神经病,可导致周围神经系统的轴突变性。 Charcot–Marie–Tooth型2D神经病(CMT2D)是由甘氨酰tRNA合成酶(GARS)的显性突变引起的。小鼠“ Gars”基因的突变导致了CMT2D的遗传和表型上有效的动物模型。 GARS中的突变如何导致周围神经病变仍存在争议。为了确定推定的疾病机制,我们比较了从“ Gars”突变小鼠的脊髓及其同窝对照中分离出的代谢物。确定了区分受影响的和未受影响的组织的改变的代谢产物的概况。抗坏血酸在CMT2D小鼠的脊髓中减少了四倍,但在血清中却没有改变。肉碱及其衍生物在突变小鼠的脊髓组织中也显着降低,而甘氨酸升高。膳食补充乙酰基-L-肉碱可改善CMT2D小鼠的总体运动能力,但乙酰基-L-肉碱和甘氨酸补充均不能改变直接评估神经病变的参数。使用临床血液化学方法验证了提示CMT2D小鼠肝肾功能不全的其他代谢物变化。通过与另一只具有类似神经肌肉功能障碍的遗传无关的小鼠品系进行比较,可以确定,这些作用并不属于神经肌肉表型。但是,这些变化似乎不是CMT2D的致病性或一致代谢产物,因为在第二只小鼠Garrs等位基因或CMT2D患者的血清样本中未观察到它们。因此,我们为CMT2D鉴定的代谢物“指纹图谱”增进了我们对与GARS突变相关的细胞生化变化的了解,但是有效的治疗策略和疾病机理的阐明尚需进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号